Here is a list of current 2018-19 EIS investment opportunities – including managed EIS funds and single company EIS offers. Click through to read our review of each EIS offer, download the documents and find full details on how to invest.
For many of the leading EIS offers you can apply online – usually the quickest way to make your EIS investment.
EIS investments are riskier than conventional investments so they're not for everyone. Before you invest you should ensure you have read and understood the product's Application Pack, our terms of business, and the Risks and Commitments.
Can’t see an offer you are interested in?
Please email us the offer details and we’ll endeavour to add it to the list below.
Invests across various technology sectors, including energy, medical and business enterprise software. Transparent – investors can see which underlying companies they will be invested in. Targets a return of £1.60 per £1 invested and should be viewed as at the upper end of the risk scale.
Parkwalk is an interesting high-growth fund that looks to back patented technology with commercial potential coming out of UK universities. The fee structure incentivises management to seek exits rather than sit on investments.
Choice of EIS or SEIS. Invests alongside business angels in early-stage, high growth potential companies carrying high investment risk. The co-investment model has benefits, and the individuals involved have strong credentials.
Calculus Capital has been at the forefront of EIS investing for years, having created the UK’s first approved EIS Fund in 1999. This offer focuses on established businesses with growth potential and will be typically split between eight to ten investments.
CHF Media Fund will invest in companies that own the intellectual property rights (IPR) to newly developed family, or children’s, television shows/concepts. Funds are used to create the IPR, which is then monetised through licensing, merchandising and broadcast sales.
Foresight Group has joined forces with Williams Advanced Engineering: the result is the Foresight Williams Technology EIS Fund. The fund invests into early-stage, unquoted companies that are developing disruptive technology and pioneering innovations, which can benefit from Williams’ technical, engineering and commercial expertise.
Jenson's first SEIS first fund was launched soon after the Seed Enterprise Investment Scheme was introduced in 2012. This sixth tranche of the Jenson SEIS and EIS fund offers a mixture of new technology investments and follow-on funding into companies previously backed by Jenson SEIS and EIS funds.
Mercia EIS Fund invests in early-stage technology and life sciences, seeking to commercialise developments from industry and spin-outs from 19 UK universities. It has a focus on the Midlands, the North of England and Scotland.
Many consider EIS appropriate for high-risk, high-growth opportunities. Technology companies seem to fit this area well as often they are not capital intensive businesses at launch, but need ongoing rounds of funding to get to market. Oxford Capital typically invest at the first round of institutional funding for these early-stage businesses.
Par Syndicate EIS is a technology growth EIS fund which co-invests with business angels from Par Equity's well established network. It focuses on the "equity gap" outside London: opportunities that are beyond the reach of an individual business angel but not quite big enough for private equity to be interested.
This EIS service invests in later stage, established growth orientated businesses. Each will typically have an annual turnover in the region of £5 million. It is likely investors will invest in a spread of unquoted and AIM listed businesses.
This fund does what the name suggests: it invests in UK start ups, alongside its network of business angels. It has shown encouraging signs to date, although past performance is not a guide to the future.
The UK is an ideas factory. And it’s slowly but surely getting better at turning great ideas into commercial successes. Many of these ideas have come out of university research projects.Indeed, Cambridge University has spun out ...
Good fund managers are choosy when it comes to investment selection. However, it’s probably fair to describe Ian Warwick, Managing Partner of Deepbridge, as downright fussy. So, what are the requirements?Firstly, to be considered for the ...
As many as 42% of paediatric clinical trials end up in failure and inconclusive results. Look at it another way: nearly half of the billions of dollars big pharma companies invest in clinical trials on children ...